Загрузка...
A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants
Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, is approved (United States and European Union; Sunosi) to treat excessive daytime sleepiness associated with narcolepsy (75‐150 mg/day) or obstructive sleep apnea (37.5‐150 mg/day). A thorough QT/QTc study assessed solriamfetol effects...
Сохранить в:
| Опубликовано в: : | Clin Pharmacol Drug Dev |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8048583/ https://ncbi.nlm.nih.gov/pubmed/32935460 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.867 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|